Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: docetaxel|DRUG: doxorubicin
Sponsor: Hospital San Carlos, Madrid
Collaborators: UNC Lineberger Comprehensive Cancer Center